Skip to main content
Fig. 3 | Multidisciplinary Respiratory Medicine

Fig. 3

From: The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models

Fig. 3

12-month adjusted* COPD-related and all-cause medical costs comparing UMEC/VI initiation at Months 1 and 12. *Adjusted for baseline and time-varying covariates, including: demographics, comorbidities, exacerbation, treatment and utilization. Month of delay in UMEC/VI treatment initiation: p = 0.044 for COPD-related medical costs; p = 0.013 for all-cause medical costs. COPD, chronic obstructive pulmonary disease; UMEC/VI, umeclidinium/vilanterol

Back to article page

Multidisciplinary Respiratory Medicine

ISSN: 2049-6958

Contact us